Acorda therapeutics to present at the cowen & company 32nd annual health care conference

Hawthorne, n.y.--(business wire)--acorda therapeutics, inc. (nasdaq: acor) today announced that ron cohen, m.d., president & ceo, will present at the cowen & company 32nd annual health care conference on monday, march 5, 2012 at 4:50 pm et at the boston marriott copley place, boston, massachusetts a live audio webcast of the presentation can be accessed under “investor events” in the investor section of the acorda website at www.acorda.com, or you may use the link: http://wsw.com/webcast/cowen6/acor/ please log in approximately 5 minutes before the scheduled time of the presentation to ensure a timely connection. an archived version of the webcast will be available until april 4, 2012 on the investors section of www.acorda.com. about acorda therapeutics acorda therapeutics is a biotechnology company developing therapies for multiple sclerosis, spinal cord injury and related nervous system disorders. the company is commercializing and marketing ampyra® (dalfampridine) extended release tablets, 10 mg, in the united states. ampyra is a potassium channel blocker approved as a treatment to improve walking in patients with multiple sclerosis (ms); this was demonstrated by an improvement in walking speed. ampyra was developed using alkermes’ matrix drug absorption system (mxdas®) technology and is manufactured by alkermes pharma ireland limited, a subsidiary of alkermes plc, based on a supply agreement with acorda. acorda also markets zanaflex capsules® (tizanidine hydrochloride), a short-acting drug for the management of spasticity. the company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain. forward-looking statements this press release includes forward-looking statements within the meaning of the private securities litigation reform act of 1995. all statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. these statements are subject to risks and uncertainties that could cause actual results to differ materially, including acorda therapeutics' ability to successfully market and sell ampyra in the united states; third party payers (including governmental agencies) may not reimburse for the use of ampyra at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions; the risk of unfavorable results from future studies of ampyra or from our other research and development programs including any acquired or in-licensed programs; the occurrence of adverse safety events with our products; delays in obtaining or failure to obtain regulatory approval of, or to successfully market, fampyra outside of the united states and our dependence on our collaboration partner biogen idec in connection therewith; competition, including the impact of generic competition on zanaflex capsules revenues; failure to protect acorda therapeutics’ intellectual property, to defend against the intellectual property claims of others or to obtain third party intellectual property licenses needed for the commercialization of our products; and the ability to obtain additional financing to support acorda therapeutics' operations. these and other risks are described in greater detail in acorda therapeutics' filings with the securities and exchange commission. acorda therapeutics may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. forward-looking statements made in this release are made only as of the date hereof, and acorda therapeutics disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
ACOR Ratings Summary
ACOR Quant Ranking